Published in Curr Opin Mol Ther on December 01, 2005
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun (2008) 1.75
Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther (2011) 0.90
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncol (2016) 0.75